Roundtable Prostate Cancer
Advertisement
The panel concludes with a discussion on how recent Medicare Part D reforms have capped patient out-of-pocket costs.
The panel transitions to role of bone-protecting agents, highlighting the importance of baseline DEXA scans.
The panel weighs some more nuanced decision-making for selecting among androgen receptor pathway inhibitors.
The panel delves into the nuanced decision-making around using doublet versus triplet systemic therapy in mHSPC.
The panel considers the challenges of applying trial data based on conventional imaging to today's PSMA PET-guided staging.
The panel explores the decision-making around offering RP to patients with borderline or undetected mHSPC on PSMA PET.
The panel discusses the role of PSMA PET imaging in staging and managing mHSPC, highlighting insurance barriers and more.
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.